Pull to refresh
Logo
Daily Brief
Following
Why Sign Up
Michael Hofman

Michael Hofman

Co-lead investigator, PRIMARY2 trial; Director, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre

Appears in 1 story

Stories

PSMA imaging reshapes prostate cancer diagnosis, cutting biopsies in half

New Capabilities

Active researcher leading multiple PSMA imaging and therapy trials

Every year, roughly 750,000 men in the United States alone undergo prostate biopsies that turn out to be unnecessary. On March 13, 2026, researchers at the European Association of Urology Congress in London presented results from the PRIMARY2 trial showing that a scan using a molecule that binds to prostate cancer cells and makes them glow on imaging cut the need for biopsies nearly in half, without missing dangerous cancers.

Updated Yesterday